Article
A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors.
Cancer research - 1 Jul 2016
Moores Sheri L, Chiu Mark L, Bushey Barbara S, Chevalier Kristen, Luistro Leopoldo, Dorn Keri, Brezski Randall J, Haytko Peter, Kelly Thomas, Wu Sheng-Jiun, Martin Pauline L, Neijssen Joost, Parren Paul W H I, Schuurman Janine, Attar Ricardo M, Laquerre Sylvie, Lorenzi Matthew V, Anderson G Mark
Abstract excerpt
Non-small cell lung cancers (NSCLC) with activating EGFR mutations become resistant to tyrosine kinase inhibitors (TKI), often through second-site mutations in EGFR (T790M) and/or activation of the cMet pathway. We engineered a bispecific EGFR-cMet antibody (JNJ-61186372) with multiple mechanisms of action to inhibit primary/secondary EGFR mutations and the cMet pathway. JNJ-61186372 blocked ligand-induced...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.